Skip to Main Content

Author Details

Oliver Hantschel
Institute of Physiological Chemistry, University of Marburg 35032 Marburg Germany .
2003
72
33
PMIDPaper TitleJournal TitlePublished Year
35975004Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl.RSC Chem Biol2022
34110462Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1<sup>T315I</sup> and BCR-ABL1<sup>T315I-E255K</sup>.Ann Hematol2021
33623882Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.Hemasphere2021
34155202Tuning SAS-6 architecture with monobodies impairs distinct steps of centriole assembly.Nat Commun2021
32353124CDK6 degradation hits Ph+ ALL hard.Blood2020
32807795Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains.Nat Commun2020
32385234Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms.Nat Commun2020
32145686Monobodies as enabling tools for structural and mechanistic biology.Curr Opin Struct Biol2020
30991025γ-Catenin-Dependent Signals Maintain BCR-ABL1<sup>+</sup> B Cell Acute Lymphoblastic Leukemia.Cancer Cell2019
31339688Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate Specificity.ACS Chem Biol2019
31025848Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins.ACS Chem Biol2019
30962580The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.Leukemia2019
29319304ATP Site Ligands Determine the Assembly State of the Abelson Kinase Regulatory Core via the Activation Loop Conformation.J Am Chem Soc2018
29249144BioSITe: A Method for Direct Detection and Quantitation of Site-Specific Biotinylation.J Proteome Res2018
28983061BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.Haematologica2018
27573554NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors.Leukemia2017
28111465Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.Leukemia2017
28347651Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.J Mol Biol2017
29185244Monobodies as possible next-generation protein therapeutics - a perspective.Swiss Med Wkly2017
29108223Bcr-Abl: one kinase, two isoforms, two diseases.Oncotarget2017
28985346Single-molecule kinetic analysis of HP1-chromatin binding reveals a dynamic network of histone modification and DNA interactions.Nucleic Acids Res2017
29235475Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.Nat Commun2017
28970898Kinase-templated abiotic reaction.Chem Sci2017
28652245Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function.Cancer Res2017
27916124Alkaline phosphatase-fused repebody as a new format of immuno-reagent for an immunoassay.Anal Chim Acta2017
26864341Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.Blood2016
26677978Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.Cancer Res2016
27682200HRD Motif as the Central Hub of the Signaling Network for Activation Loop Autophosphorylation in Abl Kinase.J Chem Theory Comput2016
26912659Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.J Biol Chem2016
270527662016 International Symposium on Chemical Biology of the NCCR Chemical Biology Campus Biotech, Geneva 13-15.1.2016.Chimia (Aarau)2016
25531586Unexpected off-targets and paradoxical pathway activation by kinase inhibitors.ACS Chem Biol2015
26039345Kinase Regulation in Mycobacterium tuberculosis: Variations on a Theme.Structure2015
25721043Targeting BCR-ABL and JAK2 in Ph+ ALL.Blood2015
25779001Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.Biochem J2015
23872305NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.Haematologica2014
25399951The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.Nat Commun2014
24412932c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.Hum Mol Genet2014
23823659Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).Leukemia2014
23277196Mechanisms of resistance to BCR-ABL and other kinase inhibitors.Biochim Biophys Acta2013
23980151Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.Proc Natl Acad Sci U S A2013
21903413Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.Crit Rev Oncol Hematol2012
23226581Structure, regulation, signaling, and targeting of abl kinases in cancer.Genes Cancer2012
23002203The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.Cancer Res2012
22975324Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis.Dev Cell2012
23148230Cell biology: a key driver of therapeutic innovation.J Cell Biol2012
22298820Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.Haematologica2012
22286129BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.Nat Chem Biol2012
22000011Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.Cell2011
22084171Targeting allosteric regulatory modules in oncoproteins: "drugging the undruggable".Oncotarget2011
19890374A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.Leukemia2010
  • 1 - 50 of 72

Recommended Authors

Diana Resetca
University of Toronto
Career Start Year 2013
Number of shared co-authors 2
Matthew S Zabriskie
University of Utah
Career Start Year 2011
Number of shared co-authors 12
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 1
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 18
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2006
Number of shared co-authors 19
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 11
Natalia Jura
Cardiovascular Research Institute, University of California San Francisco
Career Start Year 2003
Number of shared co-authors 2
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 6
Monika A Davare
Oregon Health Sciences University
Career Start Year 1998
Number of shared co-authors 9
Jennifer L Snead
University of New Mexico Health Sciences Center
Career Start Year 1998
Number of shared co-authors 7
Elie Traer
Oregon Health & Science University
Career Start Year 1998
Number of shared co-authors 16
Michael Zinda
Repare Therapeutics Inc.
Career Start Year 1998
Number of shared co-authors 2
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 6
Jack Taunton
University of California san francisco
Career Start Year 1996
Number of shared co-authors 2
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 3
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 2
Mark M Moasser
Helen Diller Family Comprehensive Cancer Center
Career Start Year 1994
Number of shared co-authors 0
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1993
Number of shared co-authors 16
Bill H Chang
Oregon Health and Science University
Career Start Year 1993
Number of shared co-authors 18
Kara Johnson
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 16
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 1991
Number of shared co-authors 20
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Career Start Year 1991
Number of shared co-authors 14
Ron Bose
Washington University School of Medicine
Career Start Year 1991
Number of shared co-authors 1
Stephan M Feller
Institute of Molecular Medicine, Martin-Luther-University of Halle-Wittenberg
Career Start Year 1989
Number of shared co-authors 2
Kevan M Shokat
University of California San Francisco
Career Start Year 1987
Number of shared co-authors 3
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 8
Neil P Shah
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 8

Collaborators

Tim K??kensh??ner
Institute for Biochemistry and Biology, University of Potsdam
Co-authored papers 6
John Kuriyan
University of California berkeley
Co-authored papers 5
Brian J Druker
Oregon Health & Science University
Co-authored papers 3
Dmitri I Svergun
King's College London BHF Centre for Research Excellence
Co-authored papers 3
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 3
Tony Pawson
Co-authored papers 2
Michael Sattler
Technical University of Munich, Institute of Structural Biology
Co-authored papers 2
Richard D Press
Oregon Health and Science University
Co-authored papers 2
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 2
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
Marco Augustin
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna
Co-authored papers 2
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 2
Stephanie G Willis
OHSU Cancer Institute
Co-authored papers 2
Lewis E Kay
University of Toronto
Co-authored papers 1
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 1
Volker D??tsch
Institute for Biophysical Chemistry, Goethe-University
Co-authored papers 1
Mateusz Koptyra
Children's Hospital of Philadelphia
Co-authored papers 1
Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Co-authored papers 1
Michael Dworzak
St. Anna Children's Cancer Research Institute (CCRI)
Co-authored papers 1
Matthew J Smalley
European Cancer Stem Cell Research Institute, Cardiff University
Co-authored papers 1
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Jorge Cortes
Georgia Cancer Center
Co-authored papers 1
Eliezer Masliah
National Institute On Aging
Co-authored papers 1
Charlotte M Niemeyer
Co-authored papers 1
Stefan Kubicek
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences
Co-authored papers 1
Thomas Decker
University of Vienna
Co-authored papers 1
Bruno C Medeiros
AbbVie Inc.
Co-authored papers 1
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Robert Kralovics
Medical University of Vienna
Co-authored papers 1
Release 1.2